News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • EyePoint's Phase 3 program for DURAVYU targets durability and safety outcomes.
  • DURAVYU has received three consecutive positive DSMC recommendations.
  • EyePoint appointed a seasoned ophthalmology commercial chief to lead commercialization efforts.
  • EyePoint reports cash runway extending into Q4 2027.
  • Analyst recommends a long trade with $14 entry, $20 target, and $10 stop.
  • Investment horizon specified at 180 trading days.

Latest Articles

EyePoint CMO Exercises Options, Sells 2,437 Shares for $36,555

EyePoint CMO Exercises Options, Sells 2,437 Shares for $36,555

EyePoint Chief Medical Officer Ramiro Ribeiro exercised 2,437 stock options and sold the same number of shares on April 17, 2026, generating $36,555 in proceeds. The sale, completed under a Rule 10b5-1 plan, follows a year of strong stock performance even as the company reported a steep revenue decline in Q4 2025 and a large full-year net loss. Sev…

NXP Announces Redemption of 3.875% Senior Notes Due 2026

NXP Announces Redemption of 3.875% Senior Notes Due 2026

NXP Semiconductors, a leading semiconductor supplier, announced the redemption of $750 million principal amount of its 3.875% senior notes due June 2026. This move demonstrates the company's commitment to effective capital management, including balanced allocation through share repurchases, dividends, and capital structure optimization. The announc…

AXT Announces Public Offering; Shares Slide After-Hours

AXT Announces Public Offering; Shares Slide After-Hours

AXT, Inc. said it will pursue a public offering of common stock, triggering a roughly 9% decline in its shares in after-hours trading. The company said proceeds will primarily support its Beijing subsidiary's capacity expansion for indium phosphide substrates for export, with remaining funds earmarked for product development, working capital and ge…

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma

BridgeBio Oncology Therapeutics announced that the FDA has granted Fast Track designation to their investigational drug BBO-11818 for treating adults with advanced KRAS-mutant pancreatic ductal adenocarcinoma. The drug, a selective pan-KRAS inhibitor, is currently in Phase 1 clinical trials and shows promising preliminary results, addressing a sign…

Kailera Therapeutics Raises $718.8 Million in IPO, Begins Trading on Nasdaq

Kailera Therapeutics Raises $718.8 Million in IPO, Begins Trading on Nasdaq

Kailera Therapeutics completed an initial public offering that generated $718.8 million in gross proceeds by selling 44,921,875 common shares at $16.00 apiece. The offering included the full exercise of an underwriters' option for 5,859,375 extra shares. Kailera began trading on the Nasdaq Global Select Market under the ticker KLRA and is developin…

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kailera Therapeutics, a clinical-stage biotech firm specializing in next-generation obesity treatments, successfully closed its initial public offering on Nasdaq under the ticker KLRA, raising $718.8 million including the full exercise of the underwriters' option. The IPO positions Kailera for continued development and commercialization of its obes…

RBB Bancorp Reports First Quarter 2026 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share

RBB Bancorp Reports First Quarter 2026 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share

RBB Bancorp announced robust financial results for Q1 2026, reporting net income of $11.3 million, or $0.66 diluted EPS, a significant increase from the previous quarter. Key metrics such as net interest margin expanded to 3.15%, nonperforming assets decreased by 9%, and loan growth continued steadily. The company declared a quarterly cash dividend…

CNB Financial Corporation Reports First Quarter 2026 Results

CNB Financial Corporation Reports First Quarter 2026 Results

CNB Financial Corporation reported Q1 2026 earnings of $26.0 million, or $0.88 per diluted share, showing improved performance compared to last year and adjusted figures in the prior quarter. Loan balances decreased slightly primarily due to prepayments on Commercial Real Estate loans, but commercial and industrial loan production remains strong. D…

Superior Group of Companies to Announce First Quarter 2026 Results

Superior Group of Companies to Announce First Quarter 2026 Results

Superior Group of Companies, Inc. (NASDAQ: SGC) announced the release of its first quarter 2026 financial results to be published before market open on May 4, 2026. The company will also host a teleconference with senior executives to discuss the results. Superior Group operates in healthcare apparel, branded products, and contact centers, focusing…

TFI International to Hold Annual Meeting of Shareholders

TFI International to Hold Annual Meeting of Shareholders

TFI International Inc., a leading North American transportation and logistics company, announced it will hold its Annual Meeting of Shareholders on April 27, 2026. Shareholders are encouraged to vote via proxy before April 23, 2026, and can attend the meeting by telephone or in person if registered. Meeting materials are available online for shareh…

Swvl Regains Compliance with Nasdaq Continued Listing Requirements

Swvl Regains Compliance with Nasdaq Continued Listing Requirements

Swvl Holdings Corp has regained compliance with Nasdaq listing standards after reporting stockholder's equity of $2.9 million and net income of $1.3 million for the year ended December 31, 2025, thereby closing the prior non-compliance notice related to minimum equity and net income requirements. The company is a technology-driven mobility solution…

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Trevi Therapeutics announced the closing of a $173 million underwritten public offering of common stock, including the full exercise of the underwriters' option to purchase additional shares. The offering proceeds will support the development of Haduvio™, an investigational therapy for chronic cough associated with pulmonary diseases.